Consistent high concentration of the viral microRNA BART17 in plasma samples from nasopharyngeal carcinoma patients - evidence of non-exosomal transport

Virology Journal

Pierre Busson⁷  Anne-Sophie Jimenez-Pailhes⁷  Philippe Lang³  Joël Guigay⁴  Fethi Guemira⁵  Véronique Schneider²  Arij Ben Chaaben⁵  Jihène Klibi⁷  Aurore Gelin⁷  Charles-Henry Gattolliat⁷  Maryse Guérin⁶  Ana Barat⁷  Benjamin Vérillaud⁸  Corinne Amiel²  François-Régis Ferrand¹  Claire Gourzones⁷ 

[1] Ecole du Val de Grâce, 1 place Alphonse Laveran, Paris 75005, France;Virology Department, Hôpital Tenon, 4 rue de la Chine, Paris 75020, France;Radiotherapy Department, Hôpital Pitié-Salpétrière, 47 Boulevard de l’hôpital, Paris 75013, France;Head and Neck Tumors Department, Institut de Cancérologie Gustave Roussy, 39 rue Camille Desmoulins, Villejuif 94805, France;Clinical Biology Department, Institut Salah Azaiz, Tunis, Tunisia;INSERM UMRS 939 - Université Pierre et Marie Curie - Paris6, Hôpital de la Pitié, 83 boulevard de l’Hôpital, Paris 75013, France;Université Paris-Sud 11, CNRS-UMR 8126 and Institut de Cancérologie Gustave Roussy, 39 rue Camille Desmoulins, Villejuif 94805, France;Head and Neck Department, Hôpital Lariboisière, 2 rue Ambroise Paré, Paris 75010, France

关键词: Plasma;    Nasopharyngeal carcinoma;    microRNA;    miR-BART;    Lipoproteins;    Head and Neck carcinomas;    Exosomes;    Epstein-Barr virus;    DNA load;    Biomarker;   

Others  :  1150798
DOI  :  10.1186/1743-422X-10-119

 received in 2012-11-29, accepted in 2013-04-02,  发布年份 2013

【 摘 要 】

Background

Because latent Epstein Barr (EBV)-infection is a specific characteristic of malignant nasopharyngeal carcinoma (NPC), various molecules of viral origin are obvious candidate biomarkers in this disease. In a previous study, we could show in a few clinical samples that it was possible to detect a category of EBV microRNAs called miR-BARTs in the plasma of at least a fraction of NPC patients. The first aim of the present study was to investigate the status of circulating miR-BART17-5p (one of the miR-BARTs hereafter called miR-BART17) and EBV DNA in a larger series of NPC plasma samples. The second aim was to determine whether or not circulating miR-BART17 was carried by plasma exosomes.

Patients and methods

Plasma samples were collected from 26 NPC patients and 10 control donors, including 9 patients with non-NPC Head and Neck squamous cell carcinoma and one healthy EBV carrier. Concentrations of miR-BART17 and two cellular microRNAs (hsa-miR-16 and -146a) were assessed by real-time quantitative PCR with spike-in normalization and absolute quantification. In addition, for 2 patients, exosome distributions of miR-BART17 and miR-16 were investigated following plasma lipoprotein fractionation by isopycnic density gradient ultrcentrifugation.

Results

The miR-BART17 was significantly more abundant in plasma samples from NPC patients compared to non-NPC donors. Above a threshold of 506 copies/mL, detection of miR-BART17 was highly specific for NPC patients (ROC curve analysis: AUC=0.87 with true positive rate = 0.77, false positive rate = 0.10). In this relatively small series, the concentration of plasma miR-BART17 and the plasma EBV DNA load were not correlated. When plasma samples were fractionated, miR-BART17 co-purified with a protein-rich fraction but not with exosomes.

Conclusions

Detection of high concentrations of plasma miR-BART17 is consistent in NPC patients. This parameter is, at least in part, independent of the viral DNA load. Circulating miR-BART17 does not co-purify with exosomes.

【 授权许可】

   
2013 Gourzones et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Feng BJ: Descriptive, environmental and genetic epidemiology of nasopharyngeal carcinoma. In Nasopharyngeal carcinoma: Keys for Translational Medicine and Biology. Edited by Bussson P. Austin and New-York: Landes and Springer; 2012:23-41. [Back N, Cohen IR, Lajtha A, Lambris JD, Paoletti R (Series Editor): Advances in Experimental Medicine and Biology]
• [2]Cai X, Schafer A, Lu S, Bilello JP, Desrosiers RC, Edwards R, Raab-Traub N, Cullen BR: Epstein-Barr virus microRNAs are evolutionarily conserved and differentially expressed. PLoS Pathog 2006, 2:e23.
• [3]Edwards RH, Marquitz AR, Raab-Traub N: Epstein-Barr virus BART microRNAs are produced from a large intron prior to splicing. J Virol 2008, 82:9094-9106.
• [4]Cosmopoulos K, Pegtel M, Hawkins J, Moffett H, Novina C, Middeldorp J, Thorley-Lawson DA: Comprehensive profiling of Epstein-Barr virus microRNAs in nasopharyngeal carcinoma. J Virol 2009, 83:2357-2367.
• [5]Zhu JY, Pfuhl T, Motsch N, Barth S, Nicholls J, Grasser F, Meister G: Identification of novel Epstein-Barr virus microRNA genes from nasopharyngeal carcinomas. J Virol 2009, 83:3333-3341.
• [6]Gourzones C, Gelin A, Bombik I, Klibi J, Verillaud B, Guigay J, Lang P, Temam S, Schneider V, Amiel C, et al.: Extra-cellular release and blood diffusion of BART viral micro-RNAs produced by EBV-infected nasopharyngeal carcinoma cells. Virol J 2010, 7:271. BioMed Central Full Text
• [7]Wong AM, Kong KL, Tsang JW, Kwong DL, Guan XY: Profiling of Epstein-Barr virus-encoded microRNAs in nasopharyngeal carcinoma reveals potential biomarkers and oncomirs. Cancer 2012, 118:698-710.
• [8]Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A, et al.: Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 2008, 105:10513-10518.
• [9]Lesnik P, Vonica A, Guerin M, Moreau M, Chapman MJ: Anticoagulant activity of tissue factor pathway inhibitor in human plasma is preferentially associated with dense subspecies of LDL and HDL and with Lp(a). Arteriosclerosis and thrombosis: a journal of vascular biology/American Heart Association 1993, 13:1066-1075.
• [10]Vickers KC, Palmisano BT, Shoucri BM, Shamburek RD, Remaley AT: MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nature cell biology 2011, 13:423-433.
• [11]Cortez MA, Bueso-Ramos C, Ferdin J, Lopez-Berestein G, Sood AK, Calin GA: MicroRNAs in body fluids–the mix of hormones and biomarkers. Nature reviews Clinical oncology 2011, 8:467-477.
• [12]Healy NA, Heneghan HM, Miller N, Osborne CK, Schiff R, Kerin MJ: Systemic mirnas as potential biomarkers for malignancy. International journal of cancer Journal international du cancer 2012, 131:2215-2222.
• [13]Cortez MA, Welsh JW, Calin GA: Circulating microRNAs as noninvasive biomarkers in breast cancer. Recent results in cancer research Fortschritte der Krebsforschung Progres dans les recherches sur le cancer 2012, 195:151-161.
• [14]Arroyo JD, Chevillet JR, Kroh EM, Ruf IK, Pritchard CC, Gibson DF, Mitchell PS, Bennett CF, Pogosova-Agadjanyan EL, Stirewalt DL, et al.: Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci U S A 2011, 108:5003-5008.
• [15]Turchinovich A, Weiz L, Langheinz A, Burwinkel B: Characterization of extracellular circulating microRNA. Nucleic Acids Res 2011, 39:7223-7233.
• [16]Gourzones C, Busson P, Raab-Traub N: Epstein-Barr Virus and the Pathogenesis of Nasopharyngeal Carcinomas. In Nasopharyngeal Carcinoma: Keys for Translational Medicine and Biology. Edited by Busson P. Austin/New-York: Landes/Springer; 2012:42-60. [Back N, Cohen IR, Lajtha A, Lambris JD, Paoletti R (Series Editor): Advances in Experimental Medicine and Biology]
• [17]Pratt ZL, Kuzembayeva M, Sengupta S, Sugden B: The microRNAs of Epstein-Barr Virus are expressed at dramatically differing levels among cell lines. Virology 2009, 386:387-397.
• [18]Hadinoto V, Shapiro M, Sun CC, Thorley-Lawson DA: The dynamics of EBV shedding implicate a central role for epithelial cells in amplifying viral output. PLoS pathogens 2009, 5:e1000496.
• [19]Wang K, Yuan Y, Cho JH, McClarty S, Baxter D, Galas DJ: Comparing the MicroRNA spectrum between serum and plasma. PLoS One 2012, 7:e41561.
• [20]Gourzones C, Jimenez AS, Busson P: Profiling of Epstein-Barr virus-encoded microRNAs in nasopharyngeal carcinoma reveals potential biomarkers and oncomirs. Cancer 2012, 118:4634. author reply 4634–4635
• [21]Meckes DG Jr, Shair KH, Marquitz AR, Kung CP, Edwards RH, Raab-Traub N: Human tumor virus utilizes exosomes for intercellular communication. Proc Natl Acad Sci U S A 2010, 107:20370-20375.
• [22]Bala S, Petrasek J, Mundkur S, Catalano D, Levin I, Ward J, Alao H, Kodys K, Szabo G: Circulating microRNAs in exosomes indicate hepatocyte injury and inflammation in alcoholic, drug-induced, and inflammatory liver diseases. Hepatology 2012, 56:1946-57.
• [23]Chan JY, Gao W, Ho WK, Wei WI, Wong TS: Overexpression of Epstein-Barr virus-encoded microRNA-BART7 in undifferentiated nasopharyngeal carcinoma. Anticancer Res 2012, 32:3201-3210.
• [24]Chan AT, Felip E: Nasopharyngeal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009, 20(Suppl 4):123-125.
• [25]Nicholls J, Niedobitek G: Histopathological diagnosis of nasopharyngeal carcinoma - Looking beyond the blue book. In Nasopharyngeal carcinoma: Keys for Translational Medicine and Biology. Edited by Busson P. Austin/New-York: Landes/Springer; 2012:10-22. [Back N, Cohen IR, Lajtha A, Lambris JD, Paoletti R (Series Editor): Advances in Experimental Medicine and Biology]
• [26]Gourzones C, Ferrand FR, Vérillaud B, Busson P: Biological tools for NPC population screening and disease monitoring. In Nasopharyngeal Carcinoma: Keys for Translational Medicine and Biology. Edited by Busson P. Austin and New-York: Landes and Springer; 2012:101-117. [Back N, Cohen IR, Lajtha A, Lambris JD, Paoletti R (Series Editor): Advances in Experimental Medicine and Biology]
• [27]Charrin S, Le Naour F, Oualid M, Billard M, Faure G, Hanash SM, Boucheix C, Rubinstein E: The major CD9 and CD81 molecular partner. Identification and characterization of the complexes. J Biol Chem 2001, 276:14329-14337.
• [28]Dehee A, Asselot C, Piolot T, Jacomet C, Rozenbaum W, Vidaud M, Garbarg-Chenon A, Nicolas JC: Quantification of Epstein-Barr virus load in peripheral blood of human immunodeficiency virus-infected patients using real-time PCR. J Med Virol 2001, 65:543-552.
• [29]Kroh EM, Parkin RK, Mitchell PS, Tewari M: Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). Methods 2010, 50:298-301.